Skip to content

Clinical trials

Terminated Hematologic Neoplasms trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Hematologic Neoplasms Status: Terminated Country / region: United States Clear all

113 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20021
20033
20043
20053
20063
20075
20093
20106
20114
20127
20132
201410
20152
20165
201710
20186
20198
20208
20219
20226
20235
20241
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Terminated113

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center13
Fred Hutchinson Cancer Center6
National Cancer Institute (NCI)5
St. Jude Children's Research Hospital5
Novartis Pharmaceuticals4
Bristol-Myers Squibb3
Fate Therapeutics3
H. Lee Moffitt Cancer Center and Research Institute3
Incyte Corporation3
Masonic Cancer Center, University of Minnesota3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Hematologic Neoplasms113
Leukemia, Myeloid, Acute22
Myelodysplastic Syndromes22
Lymphoma18
Multiple Myeloma17
Precursor Cell Lymphoblastic Leukemia-Lymphoma17
Lymphoma, Non-Hodgkin16
Hodgkin Disease13
Leukemia, Lymphocytic, Chronic, B-Cell13
Leukemia12

Trials

Showing 1 to 25 of 113. Each trial links to its page on Pharma Observatory.

13 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.